| Literature DB >> 33720009 |
William R Reay1,2, Sahar I El Shair1, Michael P Geaghan1,2, Carlos Riveros2,3, Elizabeth G Holliday2,3, Mark A McEvoy2,3, Stephen Hancock2,3, Roseanne Peel2,3, Rodney J Scott1,2, John R Attia2,3, Murray J Cairns1,2.
Abstract
Measures of lung function are heritable, and thus, we sought to utilise genetics to propose drug-repurposing candidates that could improve respiratory outcomes. Lung function measures were found to be genetically correlated with seven druggable biochemical traits, with further evidence of a causal relationship between increased fasting glucose and diminished lung function. Moreover, we developed polygenic scores for lung function specifically within pathways with known drug targets and investigated their relationship with pulmonary phenotypes and gene expression in independent cohorts to prioritise individuals who may benefit from particular drug-repurposing opportunities. A transcriptome-wide association study (TWAS) of lung function was then performed which identified several drug-gene interactions with predicted lung function increasing modes of action. Drugs that regulate blood glucose were uncovered through both polygenic scoring and TWAS methodologies. In summary, we provided genetic justification for a number of novel drug-repurposing opportunities that could improve lung function.Entities:
Keywords: GWAS; TWAS; causal inference; drug repurposing; genetics; genomics; human; lung function; polygenic scoring
Year: 2021 PMID: 33720009 DOI: 10.7554/eLife.63115
Source DB: PubMed Journal: Elife ISSN: 2050-084X Impact factor: 8.140